An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells

Mast cells are the most prominent effector cells of Type 1 hypersensitivity immune responses. CYC116 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl] pyrimidin-2-amine] is under development to be used as an anti-cancer drug, but the inhibitory effects of CYC116 on the activation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Young Hwan, Kim, Hyun Woo, Kim, Hyuk Soon, Nam, Seung Taek, Lee, Dajeong, Lee, Min Bum, Min, Keun Young, Koo, Jimo, Kim, Su Jeong, Kim, Young Mi, Kim, Hyung Sik, Choi, Wahn Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513188/
https://www.ncbi.nlm.nih.gov/pubmed/30332888
http://dx.doi.org/10.4062/biomolther.2018.148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513188/
https://www.ncbi.nlm.nih.gov/pubmed/30332888
http://dx.doi.org/10.4062/biomolther.2018.148

Ejemplares similares